News Sentiment

GELS sentiment intelligence

Gelteq Limited Ordinary Shares news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 31 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 0.53 Week of 10 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

80/100 classification confidence.

Company focus 31

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-9.4% over one week, -47.0% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Gelteq(GELS) Stock Options Chain | Quotes & News

Market Reaction

Price moving ahead of tone

66/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 80/100 classification
One-week reaction -9.4% Price reacting lower
Trend fit Trend inactive -47.0% over four weeks
Fair value -61.0% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 12
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 31
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 7
TradingKey 5
Moomoo 4
Finviz 3
GlobeNewswire 2
富途牛牛 1
Timothy Sykes 1
StocksToTrade 1

Event Lens

What the news is about

Classified themes
Market update 18
Earnings 8
Regulatory and legal 3
Balance sheet 1
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 31
Stock Titan Direct company coverage

Gelteq (GELS) wins shareholder approval and closes $2.5M second tranche note

Gelteq Limited (GELS) announced that its shareholders approved a debt financing proposal, allowing the company to close the second tranche of a convertible debt facility. This approval led to Gelteq receiving $2.5 million in proceeds from an institutional investor, net of a $375,

Tone
Neutral 50/100
Event
Regulatory and legal
Published
03 Jul 2026 03:10
Source
Stock Titan
Finviz Direct company coverage

GELS - Gelteq Ltd Short Interest

This article provides a detailed overview of Gelteq Ltd's (GELS) short interest and key financial metrics as of July 1, 2026. It includes stock performance, valuation ratios, income statement data, balance sheet figures, and insider/institutional ownership percentages. The data i

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 14:09
Source
Finviz
Finviz Direct company coverage

GELS - Gelteq Ltd Latest SEC Filings

This article provides the latest SEC filing information for Gelteq Ltd (GELS), including its last trading close of $0.6600 on July 1st, alongside a comprehensive overview of the company's financial data, performance metrics, and key ratios. It details market capitalization, incom

Tone
Negative 40/100
Event
Market update
Published
01 Jul 2026 07:09
Source
Finviz
Stock Titan Direct company coverage

Gelteq (GELS) faces $5.3M working capital deficit and rising debt

Gelteq (GELS), an Australian biotech, reported a net loss of AUD$3.74 million for the six months ended December 31, 2025, and a sharp decline in cash to AUD$9,349. The company faces severe liquidity pressure with a working capital deficit of AUD$5.34 million and rising total borr

Tone
Negative 15/100
Event
Balance sheet
Published
30 Jun 2026 21:39
Source
Stock Titan
TradingKey Direct company coverage

Gelteq Ltd (GELS) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Gelteq Ltd (GELS), including its current stock performance, market capitalization, and various analytical dimensions like financial health, valuation, price momentum, and risk assessment. It highlights that critical data for EPS, Rev

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 09:09
Source
TradingKey
TradingKey Direct company coverage

Gelteq Ltd (GELS) Institutional Confidence

This article provides details on the institutional confidence score for Gelteq Ltd (GELS), including its current stock price, market cap, and a list of major institutional shareholders. It highlights the shares held by key individuals and firms, as well as recent changes in their

Tone
Negative 41/100
Event
Market update
Published
18 Jun 2026 06:09
Source
TradingKey
TradingKey Direct company coverage

Gelteq Ltd (GELS) Valuation: PE, PB & Fair Value Analysis

This article provides a brief valuation analysis for Gelteq Ltd (GELS), highlighting key financial metrics such as P/E, P/B, P/S, and P/CF ratios. It notes that relevant data for these metrics have not yet been disclosed by the company. The article also includes current stock per

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 03:09
Source
TradingKey
TradingKey Direct company coverage

Gelteq Ltd (GELS) Financial Health: Profitability & Balance Sheet Analysis

The article provides an analysis of Gelteq Ltd's (GELS) financial health, focusing on profitability and balance sheet aspects. It notes that relevant financial data for several key metrics, including cash and cash equivalents, total assets, operating profit, and free cash flow, h

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 21:09
Source
TradingKey
富途牛牛 Direct company coverage

Gelteq Provides Corporate Update: Launching Veterinary and Human Clinical Trials, Pharmaceutical Pipeline Expanding Across Multiple Programs

Gelteq has announced a significant corporate update, detailing the launch of both veterinary and human clinical trials for its patented technology. The company also reported an expansion of its pharmaceutical pipeline across multiple programs, indicating a broader application of

Tone
Positive 72/100
Event
Market update
Published
17 Jun 2026 20:09
Source
富途牛牛
TradingKey Direct company coverage

Gelteq Ltd (GELS) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides historical dividend and stock split information for Gelteq Ltd (GELS). It notes that Gelteq Ltd has distributed $0.00 in dividends over the past five years and currently has no recorded stock split data. The company's stock is trading at $1.040 with an 8.77%

Tone
Neutral 50/100
Event
Capital return
Published
17 Jun 2026 20:09
Source
TradingKey
Stock Titan Direct company coverage

Gelteq lines up first human trial, vet study and $3.5M financing

Gelteq (NASDAQ: GELS) announced significant clinical, commercial, and financing progress, including a commenced veterinary antiparasitic trial, a first human clinical trial expected next quarter, and a preclinical diabetes study. The company secured up to $3.5 million in strategi

Tone
Positive 77/100
Event
Earnings
Published
17 Jun 2026 12:40
Source
Stock Titan
Finviz Direct company coverage

GELS - Gelteq Ltd Earnings

This article provides comprehensive financial data for Gelteq Ltd (GELS), including its market capitalization, income, sales, and various performance metrics. It details key financial ratios, EPS figures, insider ownership, institutional ownership, and stock performance over diff

Tone
Negative 15/100
Event
Earnings
Published
17 Jun 2026 03:39
Source
Finviz
Moomoo Direct company coverage

$Gelteq (GELS.US)$ thank you

This article is a brief post from a user named "Rakeem tha Dream" on the Moomoo Community platform, expressing gratitude for $Gelteq (GELS.US)$. The content highlights the social interaction aspect of the platform where users can share thoughts and engage in discussions about sto

Tone
Positive 67/100
Event
Market update
Published
16 Jun 2026 08:10
Source
Moomoo
Timothy Sykes Direct company coverage

GELS Stock Rockets On Momentum As Traders Pile In

Gelteq Limited (GELS) stock has surged by 47.47% due to strong investor optimism regarding its commercialization progress, making it a focus for momentum traders. Despite its small revenue, high price-to-sales ratio, and negative profitability, the stock has shown explosive chart

Tone
Positive 69/100
Event
Earnings
Published
15 Jun 2026 13:41
Source
Timothy Sykes
StocksToTrade Direct company coverage

GELS Stock Rockets On Massive Volume As Traders Pile In

Gelteq Limited (GELS) stock surged 48.99% on massive volume, driven by speculative trading and momentum rather than strong fundamentals. The company, with minimal revenue and negative returns, is being treated by traders as a high-volatility, high-reward opportunity, with its sto

Tone
Positive 65/100
Event
Earnings
Published
15 Jun 2026 13:41
Source
StocksToTrade
Moomoo Direct company coverage

$Gelteq (GELS.US)$ early catch…LG…🏎👍🏿🔥🔥🔥🔥🔥🏁

The article is a brief post from a user named Team Crawford on the moomoo platform, expressing enthusiasm for Gelteq (GELS.US). The post includes emojis suggesting excitement and a "good game" or "let's go" sentiment. It appears to be a social media-style update rather than an an

Tone
Positive 71/100
Event
Market update
Published
15 Jun 2026 08:40
Source
Moomoo
The Manila Times Direct company coverage

Gelteq Successfully Completes Veterinary Palatability Trials with Kemin, Further Validating Gelteq® Technology for Animal Health Applications

Gelteq announced the successful completion of veterinary palatability trials with Kemin Industries, validating their Gelteq® technology for animal health applications. The trials showed strong canine acceptance of products, even those with bitter compounds, confirming the technol

Tone
Positive 74/100
Event
Market update
Published
12 Jun 2026 18:10
Source
The Manila Times
BriefGlance Direct company coverage

Gelteq's Tasty Tech May End the Pet-Pilling War and Reshape Animal Health

Gelteq, an Australian biotech firm, has successfully completed palatability trials for its gel-based drug delivery platform, Gelteq®, in collaboration with Kemin Industries. This technology aims to solve the widespread problem of pet medication non-compliance by effectively maski

Tone
Positive 72/100
Event
Market update
Published
12 Jun 2026 17:41
Source
BriefGlance
Stock Titan Direct company coverage

Dogs accept gels that hide bitter medicine, Gelteq trials show

Gelteq (ASX:GELS) has successfully completed veterinary palatability trials with Kemin Industries, validating its gel-based delivery platform for animal health. The trials demonstrated strong canine acceptance and effective masking of bitter flavors, confirming the technology's p

Tone
Positive 90/100
Event
Market update
Published
12 Jun 2026 16:29
Source
Stock Titan
TechStock² Direct company coverage

Gelteq Jumps After GELS Hits Several Nasdaq Volatility Pauses

Shares of Gelteq Limited (NASDAQ: GELS) surged by about 56% to $0.805 on June 11, 2026, experiencing multiple Nasdaq volatility pauses as its stock price fluctuated significantly between $0.5145 and $2.01 with exceptionally high trading volume. The surge comes as the Melbourne-ba

Tone
Positive 71/100
Event
Market update
Published
11 Jun 2026 18:39
Source
TechStock²
Simply Wall Street Direct company coverage

Gelteq (Nasdaq:GELS) - Stock Analysis

This Simply Wall St analysis of Gelteq (Nasdaq:GELS) highlights its current stock performance, fundamental statistics, and recent company announcements. The report details the company's valuation, growth prospects, financial health, and risks, including its highly volatile share

Tone
Neutral 50/100
Event
Market update
Published
11 Jun 2026 17:09
Source
Simply Wall Street
BioSpectrum Asia Direct company coverage

Gelteq establishes Centre of Excellence in China to accelerate product development

Australia-based Gelteq has announced the establishment of a new Centre of Excellence in Guangdong Province, China. This strategic regional hub will strengthen Gelteq's globally integrated development platform by leveraging local infrastructure, technical expertise, and innovation

Tone
Positive 74/100
Event
Market update
Published
05 Jun 2026 15:40
Source
BioSpectrum Asia
Stock Titan Direct company coverage

Gelteq Establishes Center of Excellence in China to Accelerate Product Development and Commercial Expansion

Gelteq (GELS) has announced the establishment of a new Center of Excellence in Guangdong Province, China, aiming to accelerate product development and commercial expansion. This strategic hub will provide access to China's growing biotech and pharma ecosystem, enhancing formulati

Tone
Positive 67/100
Event
Market update
Published
04 Jun 2026 12:39
Source
Stock Titan
Stock Titan Direct company coverage

Gelteq (GELS) calls Special Meeting on convertible note share issuance and 9.99% cap

Gelteq Limited has called a Special Meeting for shareholders to approve the issuance of shares related to a new convertible note financing with an institutional investor. This approval is necessary under Nasdaq Listing Rule 5635(d) for the company to issue shares upon conversion

Tone
Neutral 50/100
Event
Regulatory and legal
Published
02 Jun 2026 20:22
Source
Stock Titan